Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Mithra Pharmaceuticals Sa (MITRA)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.22 -0.01    -3.86%
11:35:15 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Belgium
ISIN:  BE0974283153 
  • Volume: 63,556
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 0.22 - 0.23
Mithra Pharmaceuticals Sa 0.22 -0.01 -3.86%

Mithra Pharmaceuticals Sa Company Profile

 
Get an in-depth profile of Mithra Pharmaceuticals Sa, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

229

Equity Type

ORD

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Belgium, Europe and internationally. Its development candidates include Estelle, a combined oral contraceptive that has completed phase III clinical trial; Donesta, which is in phase III clinical trial for estetrol-based oral hormone treatment; and products for neuroprotection and wound healing. The company also develops Myring, a contraceptive vaginal ring releasing a combination of hormones; Tibelia, a tablet composed of tibolone and a synthetic steroid used for hormone therapy in menopause; and Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications. In addition, it provides products in polymeric forms, implants, sterile injectable products, and hormonal tablets. The company was founded in 1999 and is headquartered in Liège, Belgium.

Contact Information

Address Rue Saint-Georges 5
Liège, 4000
Belgium
Phone 32 4 349 28 22
Fax -

Top Executives

Name Age Since Title
Jacques Platieau - 2023 Independent & Non-Executive Director
Valerie Gordenne - 2021 Non-Executive Director
Jean-Michel Foidart - 2016 President of the Scientific Advisory Board & Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MITRA Comments

Write your thoughts about Mithra Pharmaceuticals Sa
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Muhammad Khawaja
Muhammad Khawaja Mar 25, 2024 8:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mithra get ready to go above 4€ in no time , the falsh will begin now
Muhammad Khawaja
Muhammad Khawaja Mar 17, 2024 7:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Who will takeover mitra?
Jo Vanrutten
Jo Vanrutten Mar 07, 2024 3:02AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
indien geen overnemer zal het game over zijn
Muhammad Khawaja
Muhammad Khawaja Feb 29, 2024 7:19PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mithra got breakthrough wow
Muhammad Khawaja
Muhammad Khawaja Feb 18, 2024 6:41PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mithra is going to be bankrupt?
Golden Age
Global_K Oct 03, 2023 6:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I can't believe analysts are still giving a 12 month price target of 5.42, this sector is always with great (investor) risks
Jo Vanrutten
Jo Vanrutten Aug 10, 2023 3:10AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
a lot of potential for the Future
Grégory Vervoort
Grégory Vervoort Aug 12, 2022 4:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mega deal to come with catalent (CTLT) ?
Filip dB
Phildb Aug 10, 2022 3:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The US Food and Drug Administration (FDA) has granted approval of the Abbreviated New Drug Application (ANDA) for HALOETTE® (etonogestrel and ethinyl estradiol) *******hormonal contraceptive ring. Mayne Pharma anticipates the commercial launch of HALOETTE® ring by early calendar year 2023.
Filip dB
Phildb Aug 01, 2022 3:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Liege, Belgium, 01 August 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that its U.S. commercial partner, Mayne Pharma Group Limited (ASX: MYX), has entered into a new strategic collaboration with GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer (DTC) program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email